Continuing Education Information
© 2017 Harborside Press®
Activity Title: The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias
Release date: 09/12/2017
Expiration date: 09/11/2018
Estimated time of completion: 1.0 hour
Media: Certified journal article
This activity is intended for advanced practice registered nurses, nurses, hematologists-oncologists, and other healthcare professionals who treat and manage refractory and relapsed lymphomas and leukemias.
At the conclusion of this activity, participants should be better able to:
- Identify key features of the mechanism of action of CAR T-cell therapies in the setting of lymphomas and leukemias
- Devise management strategies that incorporate the efficacy and safety data for CAR T-cell therapies for relapsed or refractory lymphomas and leukemias
- Integrate CAR T-cell therapy into the overall treatment plan of a patient with relapsed or refractory lymphomas and leukemias based on current evidence
- Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
Marco L. Davila, MD, PhD
Department of Blood and Marrow Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Freelancer medical writer
This activity is supported by an educational grant from Kite Pharma, Inc.
In support of improving patient care, Axis Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
The faculty have reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: Marco L. Davila, MD, PhD, received income in any amount from: Kite Pharma, GBMG, Precision Bioscience, Servier; and ownership interest in Adaptive Biotechnologies. The medical writer, Larry Rosenberg, reports that neither he nor his spouse/life partner has any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
The following planners and managers, Linda Gracie-King, MS; Jocelyn Timko; Claudine Kiffer; Larry Rosenberg; Annie Yueh; Pamela H. Viale, RN, MS, CNS, ANP; and Marilyn Haas, PhD, RN, CNS, ANP-BC, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Patricia Mangan, CRNP, has reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: advisory board for Kite Pharma; speakers bureau for Celgene, Takeda and Amgen. Stephanie Sutphin, PharmD, has reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: advisory board for Seattle Genetics and Amgen Biosimilars.
METHOD OF PARTICIPATION and CRITERIA FOR COMPLETION
There are no fees for participating and receiving CME/CNE credit for this activity. During the period from September 12, 2017, through September 11, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive credit/acknowledgment for completing this activity, please visit
http://www.axismedicaleducation.com/content/1500 and complete the post-test and evaluation.
Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be available immediately.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
How to Earn Credit
To access the learning assessment and evaluation form online, visit
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 75% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.